{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:40:46Z","timestamp":1791614446855,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Shionogi & Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40261-023-01265-8","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T14:03:15Z","timestamp":1683900195000},"page":"335-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Evaluation of the Drug\u2013Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults"],"prefix":"10.1007","volume":"43","author":[{"given":"Ryosuke","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Sonoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Kuwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"1265_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.23750\/abm.v91i1.9397","volume":"91","author":"D Cucinotta","year":"2020","unstructured":"Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157\u201360. https:\/\/doi.org\/10.23750\/abm.v91i1.9397.","journal-title":"Acta Biomed"},{"key":"1265_CR2","unstructured":"WHO. WHO coronavirus dashboard. 2022. https:\/\/covid19.who.int\/. Accessed on 23 Dec 2022."},{"key":"1265_CR3","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh Y, Uehara S, Nakahara K, Nobori H, Yamatsu Y, Yamamoto S, Maruyama Y, Taoda Y, Kasamatsu K, Suto T, Kouki K, Nakahashi A, Kawashima S, Sanaki T, Toba S, Uemura K, Mizutare T, Ando S, Sasaki M, Orba Y, Sawa H, Sato A, Sato T, Kato T, Tachibana Y. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem. 2022;65:6499\u2013512. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00117.","journal-title":"J Med Chem"},{"key":"1265_CR4","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00632-22","volume":"66","author":"R Shimizu","year":"2022","unstructured":"Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. Safety, tolerability, and pharmacokinetics of the novel antiviral agent ensitrelvir fumaric acid, a SARS-CoV-2 3CL protease inhibitor, in healthy adults. Antimicrob Agents Chemother. 2022;66: e0063222. https:\/\/doi.org\/10.1128\/aac.00632-22.","journal-title":"Antimicrob Agents Chemother"},{"key":"1265_CR5","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00697-22","volume":"66","author":"H Mukae","year":"2022","unstructured":"Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Imamura T, Sonoyama T, Fukuhara T, Ichihashi G, Sanaki T, Baba K, Takeda Y, Tsuge Y, Uehara T. A randomized phase 2\/3 study of ensitrelvir, a novel oral SARS-CoV-2 3C-like protease inhibitor, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part. Antimicrob Agents Chemother. 2022;66: e0069722. https:\/\/doi.org\/10.1128\/aac.00697-22.","journal-title":"Antimicrob Agents Chemother"},{"key":"1265_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac933","author":"H Mukae","year":"2022","unstructured":"Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Sakaguchi H, Sonoyama T, Ichihashi G, Sanaki T, Baba K, Tsuge Y, Uehara T. Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2\/3 study. Clin Infect Dis. 2022. https:\/\/doi.org\/10.1093\/cid\/ciac933.","journal-title":"Clin Infect Dis"},{"key":"1265_CR7","unstructured":"Press release on November 22, 2022. Xocova\u00ae (Ensitrelvir Fumaric Acid) tablets 125 mg approved in Japan for the treatment of SARS-CoV-2 infection, under the emergency regulatory approval system. https:\/\/www.shionogi.com\/global\/en\/news\/2022\/11\/e20221122.html. Accessed on 17 Dec 2022."},{"key":"1265_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.938552","volume":"13","author":"E Jeong","year":"2022","unstructured":"Jeong E, Nelson SD, Su Y, Malin B, Li L, Chen Y. Detecting drug\u2013drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system. Front Pharmacol. 2022;13: 938552. https:\/\/doi.org\/10.3389\/fphar.2022.938552.","journal-title":"Front Pharmacol"},{"issue":"329\u201345","key":"1265_CR9","doi-asserted-by":"publisher","first-page":"vii","DOI":"10.1016\/j.ccc.2006.02.004","volume":"22","author":"HJ Mann","year":"2006","unstructured":"Mann HJ. Drug-associated disease: cytochrome P450 interactions. Crit Care Clin. 2006;22(329\u201345):vii. https:\/\/doi.org\/10.1016\/j.ccc.2006.02.004.","journal-title":"Crit Care Clin"},{"key":"1265_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40266-021-00840-y","volume":"38","author":"D Cattaneo","year":"2021","unstructured":"Cattaneo D, Pasina L, Maggioni AP, Oreni L, Conti F, Pezzati L, Casalini G, Bonazzetti C, Morena V, Ridolfo A, Antinori S, Gervasoni C. Drug\u2013drug interactions and prescription appropriateness at hospital discharge: experience with COVID-19 patients. Drugs Aging. 2021;38:341\u20136. https:\/\/doi.org\/10.1007\/s40266-021-00840-y.","journal-title":"Drugs Aging"},{"key":"1265_CR11","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1007\/s40618-021-01604-6","volume":"44","author":"D Cattaneo","year":"2021","unstructured":"Cattaneo D, Pasina L, Conti F, Giacomelli A, Oreni L, Pezzati L, Bonazzetti C, Piscaglia M, Carrozzo G, Antinori S, Gervasoni C. Risks of potential drug\u2013drug interactions in COVID-19 patients treated with corticosteroids: a single-center experience. J Endocrinol Invest. 2021;44:2849\u201351. https:\/\/doi.org\/10.1007\/s40618-021-01604-6.","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"1265_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.6004\/jadpro.2013.4.4.7","volume":"4","author":"AM McDonnell","year":"2013","unstructured":"McDonnell AM, Dang CH. Basic review of the cytochrome P450 system. J Adv Pract Oncol. 2013;4(4):263\u20138. https:\/\/doi.org\/10.6004\/jadpro.2013.4.4.7.","journal-title":"J Adv Pract Oncol"},{"key":"1265_CR13","volume-title":"Drug development and drug interactions. Table of substrates, inhibitors and inducers","author":"FDA","year":"2020","unstructured":"FDA. Drug development and drug interactions. Table of substrates, inhibitors and inducers. Silver Spring: FDA; 2020."},{"key":"1265_CR14","doi-asserted-by":"publisher","DOI":"10.33552\/APPR.2020.02.000546","volume":"2","author":"SB Al Rihani","year":"2020","unstructured":"Al Rihani SB, Deodhar M, Dow P, Turgeon J, Michaud V. Is dexamethasone a substrate, an inducer, or a substrate-inducer of CYP3As? Arch Pharm Pharmacol Res. 2020;2: APPR.MS.ID.000546. https:\/\/doi.org\/10.33552\/APPR.2020.02.000546.","journal-title":"Arch Pharm Pharmacol Res."},{"key":"1265_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/FTD.0000000000000835","volume":"43","author":"RH Skauby","year":"2021","unstructured":"Skauby RH, Gustavsen MT, Andersen AM, Bjerre A, \u00c5sberg A, Midtvedt K, Vethe NT, Bergan S. Prednisolone and prednisone pharmacokinetics in adult renal transplant recipients. Ther Drug Monit. 2021;43:247\u201355. https:\/\/doi.org\/10.1097\/FTD.0000000000000835.","journal-title":"Ther Drug Monit"},{"key":"1265_CR16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2022.2168","volume":"182","author":"L Bouadma","year":"2022","unstructured":"Bouadma L, Mekontso-Dessap A, Burdet C, Merdji H, Poissy J, Dupuis C, Guitton C, Schwebel C, Cohen Y, Bruel C, Marzouk M, Geri G, Cerf C, M\u00e9garbane B, Gar\u00e7on P, Kipnis E, Visseaux B, Beldjoudi N, Chevret S, Timsit JF, COVIDICUS Study Group. High-dose dexamethasone and oxygen support strategies in intensive care unit patients with severe COVID-19 acute hypoxemic respiratory failure: the COVIDICUS Randomized Clinical Trial. JAMA Intern Med. 2022;182:906\u201316. https:\/\/doi.org\/10.1001\/jamainternmed.2022.2168.","journal-title":"JAMA Intern Med"},{"key":"1265_CR17","unstructured":"NIH 2022. COVID-19 treatment guidelines. https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/immunomodulators\/corticosteroids\/. Last updated:\u00a031 May 2022."},{"key":"1265_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2021436.","journal-title":"N Engl J Med"},{"key":"1265_CR19","unstructured":"WMA Declaration of Helsinki\u2014ethical principles for medical research involving human subjects. Available from: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/. Last accessed: 23 Sept 2022."},{"key":"1265_CR20","unstructured":"Council for International Organizations of Medical Sciences. International ethical guidelines for health-related research involving humans. Available from: https:\/\/cioms.ch\/wp-content\/uploads\/2017\/01\/WEB-CIOMS-EthicalGuidelines.pdf. Last accessed: 23 Sept 2022."},{"key":"1265_CR21","unstructured":"ICH International Council for Harmonisation. Efficacy guidelines. Available from: https:\/\/www.ich.org\/page\/efficacy-guidelines. Last accessed: 23 Sept 2022."},{"key":"1265_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cpdd.284","volume":"6","author":"AH Groll","year":"2017","unstructured":"Groll AH, Desai A, Han D, Howieson C, Kato K, Akhtar S, Kowalski D, Lademacher C, Lewis W, Pearlman H, Mandarino D, Yamazaki T, Townsend R. Pharmacokinetic assessment of drug\u2013drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6:76\u201385. https:\/\/doi.org\/10.1002\/cpdd.284.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1265_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cpdd.285","volume":"6","author":"R Townsend","year":"2017","unstructured":"Townsend R, Dietz A, Hale C, Akhtar S, Kowalski D, Lademacher C, Lasseter K, Pearlman H, Rammelsberg D, Schmitt-Hoffmann A, Yamazaki T, Desai A. Pharmacokinetic evaluation of CYP3A4-mediated drug\u2013drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol\/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017;6:44\u201353. https:\/\/doi.org\/10.1002\/cpdd.285.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1265_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1067\/mcp.2000.110772","volume":"68","author":"T Varis","year":"2000","unstructured":"Varis T, Kivisto KT, Backman JT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin Pharmacol Ther. 2000;68:487\u201394. https:\/\/doi.org\/10.1067\/mcp.2000.110772.","journal-title":"Clin Pharmacol Ther"},{"key":"1265_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s002280050720","volume":"56","author":"T Varis","year":"2000","unstructured":"Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol. 2000;56:57\u201360. https:\/\/doi.org\/10.1007\/s002280050720.","journal-title":"Eur J Clin Pharmacol"},{"key":"1265_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2165\/00003088-200746080-00005","volume":"46","author":"Y Ohno","year":"2007","unstructured":"Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007;46:681\u201396. https:\/\/doi.org\/10.2165\/00003088-200746080-00005.","journal-title":"Clin Pharmacokinet"},{"key":"1265_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/00003088-200847100-00004","volume":"47","author":"Y Ohno","year":"2008","unstructured":"Ohno Y, Hisaka A, Ueno M, Suzuki H. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet. 2008;47:669\u201380. https:\/\/doi.org\/10.2165\/00003088-200847100-00004.","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01265-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01265-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01265-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T09:43:00Z","timestamp":1684489380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01265-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01265-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"30 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Shionogi & Co., Ltd. The funder of the study was involved in study design, data collection, data analysis, and data interpretation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RS, TS, TF, AK, RK, and TM are employees of Shionogi & Co., Ltd. and Y.M. was an employee of Shionogi & Co., Ltd. at the time of this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines and conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation (ICH) guidelines for Good Clinical Practice (GCP).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants gave their written informed consent for participation in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization, RS, TS, TF, AK, YM; methodology, RS, YM, RK, TM; formal analysis, RS; investigation, TS; writing original draft preparation, RS; writing review and editing, RS, TS, TF, AK, YM, RK, TM. All authors have read and agreed to the published version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}